Bisaro Paul

SEC source: 0001555280-22-000095 · wf-form4_164497278680022.xml · derivative · entry 2

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,244.8149

Underlying: Common Stock · 2,673.1237 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 2,673.1237 RSUs vested on February 12, 2022; 1,613.9322 RSUs will vest on February 11, 2023; 1,438.8827 RSUs will vest on February 10, 2024; and 1,192 RSUs will vest on February 8, 2025.

F1 · derivative.exercise_price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F2 · derivative.exercise_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 2,673.1237 RSUs vested on February 12, 2022; 1,613.9322 RSUs will vest on February 11, 2023; 1,438.8827 RSUs will vest on February 10, 2024; and 1,192 RSUs will vest on February 8, 2025.

F2 · derivative.expiration_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 2,673.1237 RSUs vested on February 12, 2022; 1,613.9322 RSUs will vest on February 11, 2023; 1,438.8827 RSUs will vest on February 10, 2024; and 1,192 RSUs will vest on February 8, 2025.

SEC source: 0001555280-22-000095 · wf-form4_164497278680022.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

SEC source: 0001555280-22-000049 · wf-form4_164453606281441.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,917.9386

Underlying: Common Stock · 1,192 shares

Expires not disclosed

F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). Restricted stock units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Dividend equivalent units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant of the underlying restricted stock units, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock.

F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F4 · derivative.expiration_date: Not applicable.

F5 · balance_after: The RSUs vest as follows: 2,673.1237 RSUs will vest on February 12, 2022; 1,613.9322 RSUs will vest on February 11, 2023; 1,438.8827 RSUs will vest on February 10, 2024; and 1,192 RSUs will vest on February 8, 2025.

SEC source: 0001387131-21-008680 · ownership.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,864

F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions with prices ranging from $0.786 to $0.79 for an average weighted purchase price of $0.79. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001387131-21-008439 · ownership.xml · derivative · entry 2

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 96,864 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.

F2 · shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement.

F3 · derivative.exercise_date: The RSUs vested on June 18, 2021.

F3 · derivative.expiration_date: The RSUs vested on June 18, 2021.

F1 · derivative.underlying_shares: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.

F2 · derivative.underlying_shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement.

SEC source: 0001387131-21-008439 · ownership.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,864

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.

SEC source: 0001387131-21-007129 · ownership.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,174

Underlying: Common Stock · 99,174 shares

Expires not disclosed

F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022.

F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022.

SEC source: 0001555280-21-000120 · wf-form4_161360018202240.xml · derivative · entry 2

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,694.57

Underlying: Common Stock · 2,779.1458 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 2,779.1458 RSUs vested on February 13, 2021; 2,658.4794 RSUs will vest on February 12, 2022; 1,605.0906 RSUs will vest on February 11, 2023; and 1,431 RSUs will vest on February 10, 2024.

F1 · derivative.exercise_price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F2 · derivative.exercise_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 2,779.1458 RSUs vested on February 13, 2021; 2,658.4794 RSUs will vest on February 12, 2022; 1,605.0906 RSUs will vest on February 11, 2023; and 1,431 RSUs will vest on February 10, 2024.

F2 · derivative.expiration_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 2,779.1458 RSUs vested on February 13, 2021; 2,658.4794 RSUs will vest on February 12, 2022; 1,605.0906 RSUs will vest on February 11, 2023; and 1,431 RSUs will vest on February 10, 2024.

SEC source: 0001555280-21-000120 · wf-form4_161360018202240.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,527

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

SEC source: 0001555280-21-000071 · wf-form4_161317004477953.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,473.7158

Underlying: Common Stock · 1,431 shares

Expires not disclosed

F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). Restricted stock units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Dividend equivalent units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant of the underlying restricted stock units, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock.

F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F4 · derivative.expiration_date: Not applicable.

F5 · balance_after: The RSUs vest as follows: 2,779.1458 RSUs will vest on February 13, 2021; 2,658.4794 RSUs will vest on February 12, 2022; 1,605.0906 RSUs will vest on February 11, 2023; and 1,431 RSUs will vest on February 10, 2024.

SEC source: 0001387131-20-005822 · ownership.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,864

Underlying: Common Stock · 96,864 shares

Expires not disclosed

F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021.

F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021.

SEC source: 0001387131-20-005523 · ownership.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

SEC source: 0001555280-20-000116 · wf-form4_158215093098281.xml · derivative · entry 2

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,002.8287

Underlying: Common Stock · 3,704.6976 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 3,704.6976 RSUs vested on February 14, 2020; 2,763.4058 RSUs will vest on February 13, 2021; 2,643.4229 RSUs will vest on February 12, 2022; and 1,596 RSUs will vest on February 11, 2023.

F1 · derivative.exercise_price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F2 · derivative.exercise_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 3,704.6976 RSUs vested on February 14, 2020; 2,763.4058 RSUs will vest on February 13, 2021; 2,643.4229 RSUs will vest on February 12, 2022; and 1,596 RSUs will vest on February 11, 2023.

F2 · derivative.expiration_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 3,704.6976 RSUs vested on February 14, 2020; 2,763.4058 RSUs will vest on February 13, 2021; 2,643.4229 RSUs will vest on February 12, 2022; and 1,596 RSUs will vest on February 11, 2023.

SEC source: 0001555280-20-000116 · wf-form4_158215093098281.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,748

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

SEC source: 0001555280-20-000055 · wf-form4_158162922268531.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,707.5263

Underlying: Common Stock · 1,596 shares

Expires not disclosed

F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). Restricted stock units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Dividend equivalent units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant of the underlying restricted stock units, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock.

F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F4 · derivative.expiration_date: Not applicable.

F5 · balance_after: The RSUs vest as follows: 3,704.6976 RSUs will vest on February 14, 2020; 2,763.4058 RSUs will vest on February 13, 2021; 2,643.4229 RSUs will vest on February 12, 2022; and 1,596 RSUs will vest on February 11, 2023.

SEC source: 0001723128-19-000089 · wf-form4_155743822355516.xml · derivative · entry 3

BISARO PAUL · CIK 0001237253 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,950

Underlying: Class A Common Stock · 24,983 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 99,933 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire.

F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 99,933 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire.

SEC source: 0001723128-19-000089 · wf-form4_155743822355516.xml · nonDerivative · entry 2

BISARO PAUL · CIK 0001237253 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,454

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

SEC source: 0001723128-19-000089 · wf-form4_155743822355516.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,983

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

SEC source: 0001723128-19-000040 · wf-form4_155242353408413.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.95 per share to $11.98 per share. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc., any security holder of Amneal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001723128-19-000033 · wf-form4_155182669569421.xml · derivative · entry 2

BISARO PAUL · CIK 0001237253 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,420

Underlying: Class A Common Stock · 86,420 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2020.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2020.

SEC source: 0001723128-19-000033 · wf-form4_155182669569421.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,968

Underlying: Class A Common Stock · 175,968 shares

Expires 2029-03-01

F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 1, 2020.

SEC source: 0001555280-19-000100 · wf-form4_155078694408806.xml · derivative · entry 2

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,058.3653

Underlying: Common Stock · 4,150.3887 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 4,150.3887 RSUs vested on February 19, 2019; 3,683.0826 RSUs will vest on February 14, 2020; 2,747.2827 RSUs will vest on February 13, 2021; and 2,628.0000 RSUs will vest on February 12, 2022.

F1 · derivative.exercise_price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F2 · derivative.exercise_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 4,150.3887 RSUs vested on February 19, 2019; 3,683.0826 RSUs will vest on February 14, 2020; 2,747.2827 RSUs will vest on February 13, 2021; and 2,628.0000 RSUs will vest on February 12, 2022.

F2 · derivative.expiration_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 4,150.3887 RSUs vested on February 19, 2019; 3,683.0826 RSUs will vest on February 14, 2020; 2,747.2827 RSUs will vest on February 13, 2021; and 2,628.0000 RSUs will vest on February 12, 2022.

SEC source: 0001555280-19-000100 · wf-form4_155078694408806.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,044

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

SEC source: 0001555280-19-000042 · wf-form4_155018794265307.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,208.754

Underlying: Common Stock · 2,628 shares

Expires not disclosed

F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). Restricted stock units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Dividend equivalent units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant of the underlying restricted stock units, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock.

F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F4 · derivative.expiration_date: Not applicable.

F5 · balance_after: The RSUs vest as follows: 4,150.3887 RSUs will vest on February 19, 2019; 3,683.0826 RSUs will vest on February 14, 2020; 2,747.2827 RSUs will vest on February 13, 2021; and 2,628.0000 RSUs will vest on February 12, 2022.

SEC source: 0000899243-18-011944 · doc4.xml · derivative · entry 3

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,933

Underlying: Class A Common Stock · 99,933 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.

F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.

SEC source: 0000899243-18-011944 · doc4.xml · derivative · entry 2

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 408,719

Underlying: Class A Common Stock · 408,719 shares

Expires 2028-05-07

F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019.

SEC source: 0001003642-18-000077 · wf-form4_152581000589975.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 850,000 shares

Expires 2027-03-27

F1 · shares: Options disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017 (the "BCA"), according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock of Holdco equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA at a per-share exercise price equal to the per-share exercise price of such Option.

F1 · price: Options disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017 (the "BCA"), according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock of Holdco equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA at a per-share exercise price equal to the per-share exercise price of such Option.

F1 · derivative.exercise_date: Options disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017 (the "BCA"), according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock of Holdco equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA at a per-share exercise price equal to the per-share exercise price of such Option.

SEC source: 0000899243-18-011944 · doc4.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 850,000

Underlying: Class A Common Stock · 850,000 shares

Expires 2027-03-27

F2 · price: Received pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax Laboratories, Inc. ("Impax"), Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation in exchange for an option to purchase an equal number of shares of Impax common stock.

F1 · derivative.exercise_date: The option is vested and currently exercisable.

SEC source: 0001179110-18-006353 · edgar.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,729

F1 · shares: These restricted stock units shall vest 100% on the earlier of (i) the day before the 2019 Annual General Meeting of Shareholders and (ii) May 2, 2019.

F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001555280-18-000174 · wf-form4_152538214000483.xml · derivative · entry 2

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,529.6957

Underlying: Common Stock · 3,894.6081 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 3,894.6081 RSUs vested on May 1, 2018; 4,130.3606 RSUs will vest on February 19, 2019; 3,665.3096 RSUs will vest on February 14, 2020; and 2,734.0255 RSUs will vest on February 13, 2021.

F1 · derivative.exercise_price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

F2 · derivative.exercise_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 3,894.6081 RSUs vested on May 1, 2018; 4,130.3606 RSUs will vest on February 19, 2019; 3,665.3096 RSUs will vest on February 14, 2020; and 2,734.0255 RSUs will vest on February 13, 2021.

F2 · derivative.expiration_date: Restricted stock units previously granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). The RSUs vest as follows and are settled in Zoetis common stock upon vesting: 3,894.6081 RSUs vested on May 1, 2018; 4,130.3606 RSUs will vest on February 19, 2019; 3,665.3096 RSUs will vest on February 14, 2020; and 2,734.0255 RSUs will vest on February 13, 2021.

SEC source: 0001555280-18-000174 · wf-form4_152538214000483.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,894

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Acquisition of common stock upon vesting and settlement of restricted stock units (RSUs). Each RSU represents a right to receive one share of Zoetis Inc. common stock upon vesting of the RSU.

SEC source: 0001179110-18-006107 · edgar.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 261,744

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-18-003677 · edgar.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,332

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001555280-18-000065 · wf-form4_151873224243061.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,403.0659

Underlying: Common Stock · 2,730 shares

Expires not disclosed

F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). Restricted stock units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Dividend equivalent units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant of the underlying restricted stock units, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock.

F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F4 · derivative.expiration_date: Not applicable.

F5 · balance_after: The RSUs vest as follows: 3,888.8738 RSUs will vest on May 1, 2018; 4,124.2792 RSUs will vest on February 19, 2019; 3,659.9129 RSUs will vest on February 14, 2020; and 2,730 RSUs will vest on February 13, 2021.

SEC source: 0001179110-18-000112 · edgar.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,253

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-013548 · edgar.xml · derivative · entry 3

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 37,727 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

F2 · price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

F2 · derivative.exercise_date: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

F2 · derivative.expiration_date: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

SEC source: 0001179110-17-013548 · edgar.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,774

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest in equal installments on each of December 31, 2017, December 31, 2018 and December 31, 2019.

F2 · price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

F3 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-006734 · edgar.xml · nonDerivative · entry 2

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,047

F2 · shares: These restricted stock units shall vest 100% on the earlier of (i) the day before the 2018 Annual General Meeting of Shareholders or (ii) May 4, 2018.

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-006734 · edgar.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,824

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0000911916-17-000143 · edgar.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,095.293

Underlying: Common Stock · 97.745 shares

Expires not disclosed

F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors.

F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1.

F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.

F4 · balance_after: Includes 5.918 phantom stock units accrued on January 27, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0001003642-17-000029 · wf-form4_149082598118332.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 850,000

Underlying: Common Stock · 850,000 shares

Expires 2027-03-27

F1 · derivative.exercise_date: The option vests in four equal installments beginning on March 27, 2018, which is the first anniversary of the grant date.

SEC source: 0001179110-17-004107 · edgar.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,038

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-003930 · edgar.xml · nonDerivative · entry 4

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,900

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $248.33 to $248.45, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent.

F5 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-003930 · edgar.xml · nonDerivative · entry 3

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,271

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $247.22 to $248.21, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent.

SEC source: 0001179110-17-003930 · edgar.xml · nonDerivative · entry 2

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,959

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $246.21 to $247.02, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent.

SEC source: 0001179110-17-003930 · edgar.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 274,226

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $245.21 to $246.17, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001555280-17-000055 · wf-form4_148728256539213.xml · derivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,593.6076

Underlying: Common Stock · 3,635 shares

Expires not disclosed

F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (each an "RSU" and collectively, "RSUs"). Restricted stock units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Dividend equivalent units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant of the underlying restricted stock units, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock.

F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events.

F4 · derivative.expiration_date: Not applicable.

F5 · balance_after: The RSUs vest as follows: 3,862.4023 RSUs will vest on May 1, 2018; 4,096.2053 RSUs will vest on February 19, 2019; and 3,635 RSUs will vest on February 14, 2020.

SEC source: 0001179110-17-001834 · edgar.xml · nonDerivative · entry 1

BISARO PAUL · CIK 0001237253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,900

F1 · shares: These restricted stock units shall vest 100% on the earlier of (i) the day before the 2017 Annual Shareholder Meeting or (ii) May 4, 2017.

F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-001736 · edgar.xml · derivative · entry 3

BISARO PAUL · CIK 0001237253 · Director · Exec Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 7,105 shares

Expires 2017-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Represents performance-based restricted share units ("PSUs") which vested on February 1, 2017, following certification of achievement by issuer of certain performance criteria. Each PSU represented a contingent right to receive ordinary shares of the Issuer equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and Reporting Person.

F2 · derivative.expiration_date: Represents performance-based restricted share units ("PSUs") which vested on February 1, 2017, following certification of achievement by issuer of certain performance criteria. Each PSU represented a contingent right to receive ordinary shares of the Issuer equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and Reporting Person.

SEC source: 0001179110-17-001736 · edgar.xml · nonDerivative · entry 2

BISARO PAUL · CIK 0001237253 · Director · Exec Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,456

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.